Your browser doesn't support javascript.
loading
Management of cognitive impairment in bipolar disorder: a systematic review of randomized controlled trials.
Tamura, Jocelyn K; Carvalho, Isabelle P; Leanna, Lui M W; Feng, Jia Nuo; Rosenblat, Joshua D; Mansur, Rodrigo; Lee, Yena; Cha, Danielle S; Teopiz, Kayla; Ahmad, Zara; Nasri, Flora; Kim, Jiin; McIntyre, Roger S.
  • Tamura JK; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Carvalho IP; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Leanna LMW; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Feng JN; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Rosenblat JD; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Mansur R; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Lee Y; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Cha DS; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
  • Teopiz K; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Ahmad Z; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Nasri F; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • Kim J; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
  • McIntyre RS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.
CNS Spectr ; : 1-22, 2021 Jan 28.
Article en En | MEDLINE | ID: mdl-33706820
ABSTRACT
Cognitive impairment is common in bipolar disorder and is emerging as a therapeutic target to enhance quality of life and function. A systematic search was conducted on PubMed, PsycInfo, Cochrane, clinicaltrials.gov, and Embase databases for blinded or open-label randomized controlled trials evaluating the pro-cognitive effects of pharmacological, neurostimulation, or psychological interventions for bipolar disorder. Twenty-two trials were identified, evaluating a total of 16 different pro-cognitive interventions. The methodological quality of the identified trials were assessed using the Cochrane Risk of Bias tool. Currently, no intervention (i.e., pharmacologic, neurostimulation, cognitive remediation) has demonstrated robust and independent pro-cognitive effects in adults with bipolar disorder. Findings are preliminary and methodological limitations limit the interpretation of results. Methodological considerations including, but not limited to, the enrichment with populations with pre-treatment cognitive impairment, as well as the inclusion of individuals who are in remission are encouraged. Future trials may also consider targeting interventions to specific cognitive subgroups and the use of biomarkers of cognitive function.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Año: 2021 Tipo del documento: Article